The adenovirus E4-ORF3 protein stimulates SUMOylation of general transcription factor TFII-I to direct proteasomal degradation

mBio

Volumn 7, Issue 1, 2016, Pages

  Bridges, Rebecca G ^a   Sohn, Sook Young ^a   Wright, Jordan ^b,c   Leppard, Keith N ^b   Hearing, Patrick ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c OXFORD BIOMEDICA UK LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEASOME; PROTEIN E4 ORF3; SUMO 1 PROTEIN; SUMO 3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR II I; UNCLASSIFIED DRUG; VIRUS PROTEIN; SUMO PROTEIN; TRANSCRIPTION ELONGATION FACTOR; TRANSCRIPTION FACTOR S-II; UBIQUITIN; VIRAL PROTEIN;

ADENOVIRUS INFECTION; ARTICLE; CONTROLLED STUDY; ENZYME DEGRADATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN ADENOVIRUS C; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SUMOYLATION; UBIQUITINATION; HELA CELL LINE; HOST PATHOGEN INTERACTION; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN DEGRADATION;

ADENOVIRUSES, HUMAN; HELA CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; PROTEOLYSIS; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SUMOYLATION; TRANSCRIPTIONAL ELONGATION FACTORS; UBIQUITIN; UBIQUITINATION; VIRAL PROTEINS;

EID: 84960158289     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.02184-15     Document Type: Article

References (40)

1. Echavarría M. 2008. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev 21:704–715. http://dx.doi.org/10.1128/CMR.00052-07.
2. Berk AJ. 2005. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 24:7673–7685. http://dx.doi.org/10.1038/sj.onc.1209040.
3. Hendrickx R, Stichling N, Koelen J, Kuryk L, Lipiec A, Greber UF. 2014. Innate immunity to adenovirus. Hum Gene Ther 25:265–284. http://dx.doi.org/10.1089/hum.2014.001.
4. Weitzman MD, Ornelles DA. 2005. Inactivating intracellular antiviral responses during adenovirus infection. Oncogene 24:7686–7696. http://dx.doi.org/10.1038/sj.onc.1209063.
5. Doucas V, Ishov AM, Romo A, Juguilon H, Weitzman MD, Evans RM, Maul GG. 1996. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev 10:196–207. http://dx.doi.org/10.1101/gad.10.2.196.
6. Leppard KN, Emmott E, Cortese MS, Rich T. 2009. Adenovirus type 5 E4 Orf3 protein targets promyelocytic leukaemia (PML) protein nuclear domains for disruption via a sequence in PML isoform II that is predicted as a protein interaction site by bioinformatic analysis. J Gen Virol 90:95–104. http://dx.doi.org/10.1099/vir.0.005512-0.
7. Ullman AJ, Hearing P. 2008. Cellular proteins PML and Daxx mediate an innate antiviral defense antagonized by the adenovirus E4 ORF3 protein. J Virol 82:7325–7335. http://dx.doi.org/10.1128/JVI.00723-08.
8. Evans JD, Hearing P. 2005. Relocalization of the Mre11-Rad50-Nbs1 complex by the adenovirus E4 ORF3 protein is required for viral replication. J Virol 79:6207-6215. http://dx.doi.org/10.1128/JVI.79.10.6207-6215.2005.
9. Stracker TH, Carson CT, Weitzman MD. 2002. Adenovirus oncoproteins inactivate the Mre11-Rad50-NBS1 DNA repair complex. Nature 418:348–352. http://dx.doi.org/10.1038/nature00863.
10. Schreiner S, Wimmer P, Dobner T. 2012. Adenovirus degradation of cellular proteins. Future Microbiol 7:211–225. http://dx.doi.org/10.2217/fmb.11.153.
11. Gareau JR, Lima CD. 2010. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol 11:861–871. http://dx.doi.org/10.1038/nrm3011.
12. Everett RD, Boutell C, Hale BG. 2013. Interplay between viruses and host sumoylation pathways. Nat Rev Microbiol 11:400–411. http://dx.doi.org/10.1038/nrmicro3015.
13. Randow F, Lehner PJ. 2009. Viral avoidance and exploitation of the ubiquitin system. Nat Cell Biol 11:527–534. http://dx.doi.org/10.1038/ncb0509-527.
14. Sohn SY, Hearing P. 2012. Adenovirus regulates sumoylation of Mre11- Rad50-Nbs1 components through a paralog-specific mechanism. J Virol 86:9656–9665. http://dx.doi.org/10.1128/JVI.01273-12.
15. Leppard KN, Everett RD. 1999. The adenovirus type 5 E1b 55K and E4 Orf3 proteins associate in infected cells and affect ND10 components. J Gen Virol 80(Pt 4):997–1008. http://dx.doi.org/10.1099/0022-1317-80-4-997.
16. Sohn SY, Bridges RG, Hearing P. 2015. Proteomic analysis of ubiquitinlike posttranslational modifications induced by the adenovirus E4-ORF3 protein. J Virol 89:1744–1755. http://dx.doi.org/10.1128/JVI.02892-14.
17. Roy AL. 2012. Biochemistry and biology of the inducible multifunctional transcription factor TFII-I: 10 years later. Gene 492:32-41. http://dx.doi.org/10.1016/j.gene.2011.10.030.
18. Wright J, Atwan Z, Morris SJ, Leppard KN. 2015. The human adenovirus type 5 L4 promoter is negatively regulated by TFII-I and L4-33K. J Virol 89:7053–7063. http://dx.doi.org/10.1128/JVI.00683-15.
19. Novina CD, Cheriyath V, Roy AL. 1998. Regulation of TFII-I activity by phosphorylation. J Biol Chem 273:33443–33448. http://dx.doi.org/10.1074/jbc.273.50.33443.
20. Desgranges ZP, Ahn J, Lazebnik MB, Ashworth T, Lee C, Pestell RC, Rosenberg N, Prives C, Roy AL. 2005. Inhibition of TFII-I-dependent cell cycle regulation by p53. Mol Cell Biol 25:10940-10952. http://dx.doi.org/10.1128/MCB.25.24.10940-10952.2005.
21. Barysch SV, Dittner C, Flotho A, Becker J, Melchior F. 2014. Identification and analysis of endogenous SUMO1 and SUMO2/3 targets in mammalian cells and tissues using monoclonal antibodies. Nat Protoc 9:896–909. http://dx.doi.org/10.1038/nprot.2014.053.
22. Forrester NA, Patel RN, Speiseder T, Groitl P, Sedgwick GG, Shimwell NJ, Seed RI, Catnaigh PO, McCabe CJ, Stewart GS, Dobner T, Grand RJ, Martin A, Turnell AS. 2012. Adenovirus E4orf3 targets transcriptional intermediary factor 1gamma for proteasome-dependent degradation during infection. J Virol 86:3167–3179. http://dx.doi.org/10.1128/JVI.06583-11.
23. Patsalo V, Yondola MA, Luan B, Shoshani I, Kisker C, Green DF, Raleigh DP, Hearing P. 2012. Biophysical and functional analyses suggest that adenovirus E4-ORF3 protein requires higher-order multimerization to function against promyelocytic leukemia protein nuclear bodies. J Biol Chem 287:22573–22583. http://dx.doi.org/10.1074/jbc.M112.344234.
24. Evans JD, Hearing P. 2003. Distinct roles of the adenovirus E4 ORF3 protein in viral DNA replication and inhibition of genome concatenation. J Virol 77:5295–5304. http://dx.doi.org/10.1128/JVI.77.9.5295-5304.2003.
25. Stracker TH, Lee DV, Carson CT, Araujo FD, Ornelles DA, Weitzman MD. 2005. Serotype-specific reorganization of the Mre11 complex by adenoviral E4orf3 proteins. J Virol 79:6664-6673. http://dx.doi.org/10.1128/JVI.79.11.6664-6673.2005.
26. Soria C, Estermann FE, Espantman KC, O’Shea CC. 2010. Heterochromatin silencing of p53 target genes by a small viral protein. Nature 466: 1076–1081. http://dx.doi.org/10.1038/nature09307.
27. Vink EI, Zheng Y, Yeasmin R, Stamminger T, Krug LT, Hearing P. 2015. Impact of adenovirus E4-ORF3 oligomerization and protein localization on cellular gene expression. Viruses 7:2428-2449. http://dx.doi.org/10.3390/v7052428.
28. Morris SJ, Scott GE, Leppard KN. 2010. Adenovirus late-phase infection is controlled by a novel L4 promoter. J Virol 84:7096-7104. http://dx.doi.org/10.1128/JVI.00107-10.
29. Wright J, Leppard KN. 2013. The human adenovirus 5 L4 promoter is activated by cellular stress response protein p53. J Virol 87:11617–11625. http://dx.doi.org/10.1128/JVI.01924-13.
30. Huang MM, Hearing P. 1989. Adenovirus early region 4 encodes two gene products with redundant effects in lytic infection. J Virol 63: 2605–2615.
31. Ou HD, Kwiatkowski W, Deerinck TJ, Noske A, Blain KY, Land HS, Soria C, Powers CJ, May AP, Shu X, Tsien RY, Fitzpatrick JA, Long JA, Ellisman MH, Choe S, O’Shea CC. 2012. A structural basis for the assembly and functions of a viral polymer that inactivates multiple tumor suppressors. Cell 151:304-319. http://dx.doi.org/10.1016/j.cell.2012.08.035.
32. Higginbotham JM, O’Shea CC. 2015. Adenovirus E4-ORF3 targets PIAS3 and together with E1B-55K remodels SUMO interactions in the nucleus and at virus genome replication domains. J Virol 89:10260–10272. http://dx.doi.org/10.1128/JVI.01091-15.
33. Cheng CY, Gilson T, Dallaire F, Ketner G, Branton PE, Blanchette P. 2011. The E4orf6/E1B55K E3 ubiquitin ligase complexes of human adenoviruses exhibit heterogeneity in composition and substrate specificity. J Virol 85:765–775. http://dx.doi.org/10.1128/JVI.01890-10.
34. Forrester NA, Sedgwick GG, Thomas A, Blackford AN, Speiseder T, Dobner T, Byrd PJ, Stewart GS, Turnell AS, Grand RJ. 2011. Serotypespecific inactivation of the cellular DNA damage response during adenovirus infection. J Virol 85:2201–2211. http://dx.doi.org/10.1128/JVI.01748-10.
35. Sriramachandran AM, Dohmen RJ. 2014. SUMO-targeted ubiquitin ligases. Biochim Biophys Acta 1843:75-85. http://dx.doi.org/10.1016/j.bbamcr.2013.08.022.
36. Poulsen SL, Hansen RK, Wagner SA, van Cuijk L, van Belle GJ, Streicher W, Wikström M, Choudhary C, Houtsmuller AB, Marteijn JA, Bekker-Jensen S, Mailand N. 2013. RNF111/Arkadia is a SUMOtargeted ubiquitin ligase that facilitates the DNA damage response. J Cell Biol 201:797–807. http://dx.doi.org/10.1083/jcb.201212075.
37. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG, Palvimo JJ, Hay RT. 2008. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 10:538–546. http://dx.doi.org/10.1038/ncb1716.
38. Boutell C, Cuchet-Lourenço D, Vanni E, Orr A, Glass M, McFarlane S, Everett RD. 2011.Aviral ubiquitin ligase has substrate preferentialSUMO targeted ubiquitin ligase activity that counteracts intrinsic antiviral defence. PLoS Pathog 7:e1002245. http://dx.doi.org/10.1371/journal.ppat.1002245.
39. Evans VC, Barker G, Heesom KJ, Fan J, Bessant C, Matthews DA. 2012. De novo derivation of proteomes from transcriptomes for transcript and protein identification. Nat Methods 9:1207–1211. http://dx.doi.org/10.1038/nmeth.2227.
40. Tatham MH, Rodriguez MS, Xirodimas DP, Hay RT. 2009. Detection of protein SUMOylation in vivo. Nat Protoc 4:1363–1371. http://dx.doi.org/10.1038/nprot.2009.128.